CompletedPhase 2NCT02276872
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- United Therapeutics
- Principal Investigator
- Dunbar Ivy, MDDenver Children's Hospital
- Intervention
- oral treprostinil(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 7-17 years · All sexes
- Timeline
- 2014 – 2017
Study locations (9)
- Lucile Packard Children's Hospital, Palo Alto, California, United States
- University of California San Francisco, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02276872 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
- RECRUITINGNCT07013149The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial HypertensionUniversity of Sao Paulo General Hospital
- RECRUITINGNCT06998329PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArchUniversity of Sao Paulo General Hospital
- ENROLLING BY INVITATIONPHASE2NCT06992440Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionGustavo A Heresi, MD, MS
- RECRUITINGNANCT06968962Comparison of Sequential to Initial Combination Therapy in PAHSecond Affiliated Hospital, School of Medicine, Zhejiang University
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →